Alopecia areata is more prevalent in patients with IBD, especially those on anti-TNF therapy, compared with controls. The study found no significant difference in alopecia improvement between ...

Upadacitinib, a JAK1 inhibitor, is effective for inflammatory conditions but may induce alopecia areata in some patients. A case study reported alopecia areata in a patient after nearly a year of ...

No associations were found between prior use of topicals, systemic immunosuppressants, intralesional corticosteroids, or topical immunotherapy and efficacy of ritlecitinib 30 mg or greater at 48 weeks ...

ROCHESTER — Department-wide staffing changes, including layoffs in some cases, are happening at Mayo Clinic. Officials at Mayo Clinic describe the changes as a process to “grow and evolve its ...

Pfizer’s JAK/TEC inhibitor Litfulo has been recommended for NHS use as a treatment for hair loss caused by severe alopecia areata, the first drug therapy for a condition that affects around ...

revealing diffuse alopecia areata-like hair loss in a patient. A 28-year-old woman with well-controlled polycystic ovary syndrome presented with a 7-month history of hair loss after a tick bite on her ...

A new study published in the journal of Dermatology suggests that the Alopecia areata patients who were receiving doses of active ritlecitinib reported better outcomes in terms of satisfaction with ...

Bariatric and metabolic surgery in the adult population.